E32: Behind the scenes of Elon hosting SNL, CDC failures, America's real-time UBI experiment & more

Jason Calacanis was more than an observer during Elon Musk’s SNL week: Musk invited him into the writers’ room as a “wingman,” and staff sometimes used him as an intermediary. Calacanis says he negotiated the show’s initial resistance to Dogecoin and cryptocurrency references and contributed punch-ups to Musk’s monologue.

Calacanis says he wrote the core Asperger’s monologue joke and supplied the O.J. Simpson punch line that Colin Jost immediately kept. After the Asperger’s line landed, several staffers reportedly became emotional, including a wardrobe worker who said her son had been beaten up for having Asperger’s.

The episode’s sharpest macro warning came from Stanley Druckenmiller’s argument that emergency monetary policy had continued after demand recovered. He said the Fed had added $2.5 trillion of post-vaccine QE, was buying 60% of new Treasury issuance, and could eventually face interest costs equal to 30% of the federal budget.

The labor shortage was already producing unusually strong wage signals in service work. The hosts cited Chipotle moving to a $15 minimum wage and advertising a path to $100,000 annual pay, Uber reporting roughly $38 hourly earnings for some New York drivers, and Montana offering $1,200 to return to work.

David Sacks said he personally sought out the Chesa Boudin recall effort and donated $25,000 rather than waiting to be approached. He linked that activism to the podcast’s “go direct” strategy: bypassing reporters and using an audience the hosts said had reached about one million weekly views or listens. (San Francisco Chronicle)

Synthetic-biology capital was far ahead of operating results: Zymergen listed near $5 billion on roughly $13–14 million of revenue, while Ginkgo Bioworks announced a roughly $15 billion SPAC valuation with under $100 million of revenue. The speakers treated those deals as validation that capital was available, not proof that the business model was mature.

Chamath Palihapitiya said he was betting his career, capital and time on synthetic biology and had several businesses competing with Ginkgo and Zymergen in different ways. He also said the sector still had not determined whether durable value would sit in tools, manufacturing infrastructure or end products.

Pivot Bio supplied the episode’s clearest example of synthetic biology becoming a real product rather than a laboratory promise. The discussion described microbes applied to seeds that pull nitrogen from the air, potentially reducing synthetic fertilizer use and the energy and nitrous-oxide emissions associated with conventional ammonia production.